glucose load, they do not show the normal suppressive effect on serum GH levels (Roth et al. 1964 , Earll et al. 1967 , Sonksen et af. 1967 , and some exhibit a paradoxical increase (Beck et al. 1966 , Jadresic et al. 1982 . They present disrupted regulatory responses of GH, such as the release of GH after the administration of thyrotropin-releasing hormone (TRH) (Irie & Tsushima 1972) or luteinizing hormone-releasing hormone (LHRH) (Rubin et al. 1973) , which does not occur in normal subjects, and the suppression of GH following the administration of bromocriptine and other dopaminergic drugs , which is contrary to what happens in normal individuals. But the restitution to normal physiological response after resection of microadenomas would not favour an underlying hypothalamic defect. Hanew et al. (1980) and Pieters et al. (1982) distinguished two groups of acromegalies by their differing sensitivities to somatostatin, giving support to the idea that some patients present with autonomously-functioning pituitary adenomas, while the condition in others is primarily caused by hypothalamic derangement. Plasma PRL is elevated in about one-third of acromegalic patients, paralleling the level in GH before and after treatment (Lamberts et al. 1979) . It has been observed that the peculiar response of some acromegalic patients to TRH returns to normal after selective removal of a pituitary microadenoma (Hoyte & Martin 1975) . In vitro. GH secretion of pituitary adenomas can be stimulated by TRH (Ishibashi & Yamaji 1978) and inhibited by bromocriptine (Mashiter et al. 1977), demonstrating that both have a direct action on the pituitary.
There are contradictory results regarding whether mixed pituitary adenomas are composed of one cell type that secretes both GH and PRL or two distinct types. Immunochemical studies at necropsy have shown that the majority of pituitary adenomas (45/66) are mixed and contain two or more hormones (Heitz 1979) .
Somatomedins
Some of the effects of GH on peripheral tissues are not exerted directly but are mediated by inducing the formation of a second messenger, a group of polypeptides with insulin-like activity, the somatomedins or insulin-like growth hormone factors (IGF). They include somatomedin-A, somatomedin-C, IGF-I and IGF-2 (formerly known as 'nonsuppressible insulin-like activity') and multiplication-stimulating activity (MSA) (Phillips & Vassilopoulou-Sellin 1980) . IGF-I and IGF-2 have been isolated and their structures established (Rinderknecht & Humbel 1978a. b) . Immunologically and in its receptor binding IGF-I appears to be identical to somatomedin-C. For this reason the term 'somatomedin CjIGF-I" has been proposed . Somatomedin A and MSA also crossreact with somatomedin-C antibodies (Hall et al. 1979) . Somatomedin-C, IGF-I and somatomedin-A are closely related or identical and are highly GH-dependent. Very low concentrations of these peptides are observed in hypopituitarism and elevations as much as 5-10 times normal are found in acromegaly. IGF-2 has not been found increased in acromegaly and its regulation seems to be different from IGF-I (Daughaday et al. 1981 ), although Merimee et al. (1982 have found that IGF-2, like IGF-I, is GH-dependent and hence also a somatomedin.
Diagnosis and assessment of acromegalic activity
The diagnosis of acromegaly and the assessment of acromegalic activity are currently confirmed by measuring serum GH repeatedly after overnight fasting or after an oral glucose tolerance test (GIT). The majority of acromegalic patients have random serum GH concentrations which are so high as to be diagnostic, but occasionally multiple sampling is required to define the hormonal status due to large spontaneous fluctuations and to values overlapping the normal range. Some cases have been described with normal basal GH levels but abnormal GH secretory patterns (Cryer & Daughaday 1969 , Mims & Bethune 1974 or elevated somatomedin levels (Hoffenberg et al. 1977 , Feingold et al. 1979 , Clemmons et al. 1979 . A single isolated high GH value does not necessarily indicate acromegaly. It has been established that a rising blood glucose suppresses the secretion of GH in normal persons but rarely does so in acromegalic patients, or its effect is only partial or paradoxical (Roth et al. 1964 , Beck et al. 1966 , Earll et al. 1967 . Failure of the serum GH level to suppress below 5 miu/l will usually be considered diagnostic. Among 155 acromegalies studied at the Hammersmith Hospital, GH values during a GTT were found to range from 8 to 1833 miujl (Jadresic et al. 1982) .
The GH dependence of somatomedins (Daughaday et al. 1972) and their long half-life due to their binding to specific carrier proteins (Kaufmann et al. 1977 ) make them a good index of GH secretion in acromegaly (Phillips & Vassilopoulou-Sellin 1980 , Furnaletto et al. 1977 , Clemmons et al. 1979 . Rieu et al. (1982) have found a significant correlation between both IGF and GH levels and the clinical activity of the disease. Somatomedin-C levels should theoretically be less labile than GH levels. But, in the experience of Stonesifer et al. (1981) , somatomedin-C did not prove more advantageous than GH in assessing activity in treated acromegalies, and they concluded that since GH determinations are less costly, easier to perform and tend to reflect activity in a larger number of patients, serum GH still appears to be the most useful laboratory test.
As already mentioned, the administration of TRH (Irie & Tsushima 1972) and LHRH (Rubin et al. 1973 , Faglia et al. 1973 ) increase serum GH levels in a considerable number of acromegalies, and has been proposed as a test to define activity.
Radiological investigations
Computerized axial tomography (CT) has introduced a major advantage in the assessment of pituitary tumours. Most macroadenomas can be recognized on plain skull X-ray films. In some patients, asymmetric growth will produce a clearly-defined double floor in coned views of the sella. Definite but not obvious tumours (Category 2 in the scale of Doyle 1979) usually require tomography for confirmation. The fourth-generation CT scanners allow the recognition of microadenomas in sellas Category 3 and 4 and also in normal sellas (Category 5) (lung et al. 1982) . The diagnosis of microadenomas is often based on endocrine and not radiological criteria, and the search for radiological changes is aimed at helping the neurosurgeon. CT scans, particularly after the injection of a radiological contrast agent, provide a useful examination of the suprasellar area and will detect most superior extensions of pituitary tumours (Hall & McAllister 1980) . The CT scan has come to replace the rather painful combination of anteroposterior and lateral tomography with pneumoencephalography for the same purpose, and also allows parasellar extensions to be located· (Banna et al. 1980 , Kricheff 1979 . Cerebral angiography is required if an intrasellar carotid aneurysm or meningioma has to be excluded, and should be carried out preoperatively in tumours presenting with parasellar extension (Baker 1972 , Thern et al. 1979 ).
Treatment
Currently-available treatments for acromegaly include surgical ablation of pituitary tumours, external conventional supervoltage or heavy-particle pituitary irradiation, interstitial irradiation by implantation of radioactive seeds and medical treatment. There is much debate about the relative merits and risks of these alternative therapies. The therapeutic aims in selecting among these modalities are reduction of serum GH levels to normal, elimination of problems related to the tumour growth, and preservation or restoration of normal pituitary function if possible.
Medical treatment
Several attempts have been made in the past to treat acromegaly medically. The early observation that oestrogens could diminish some signs and symptoms of acromegaly has been found to be independent of any effect on serum GH levels (Schwartz et al. 1969 ) but correlated with a reduction in serum somatomedin-C (Clemmons et al. 1980) , perhaps through a peripheral action of oestrogens antagonizing GH on target tissues. Medroxiprogesterone is effective in lowering GH levels and in improving symptoms in some patients (Lawrence & Kirsteins 1970 , Malarkey & Daughaday 1971 . Phentolamine, an 'alpha-adrenergic antagonist (Nakagawa & Mashimo 1973) , and also the antiserotonin agents metergoline and cyproheptadine (Feldman et al. 1976 , Delitalia et al. 1976 ) have 'been tried with some effect. The administration of dopaminergic drugs, such as L-dopa (Liuzzi et al. 1972) , apomorphine , dopamine ) and bromocriptine , Camanni et al. 1975 , that increase serum GH in normal subjects, have been found to exert a significant inhibitory effect on GH secretionin more than 50% of acromegalic patients.
Current trials for the pharmacological treatment of acromegaly are mainly being carried out with somatostatin and its derivatives, a variety of dopaminergic drugs, and some dopamine antagonists.
Somatostatin and its derivatives: Somatostatin is a tetrapeptide (Brazeau et al. 1973) produced in the hypothalamus and other sites controlling serum GH by inhibiting its release. It acts directly upon the pituitary, leading to a sharp drop in GH levels (Besser et al. 1974 ). Somatostatin has a very short half-life and needs to be administered by constant infusion. It also diminishes the secretion of other hormones such as insulin (Alberti et al. 1973) , glucagon ) and TSH (Hall et al. 1978) , and it is possible that given in sufficient dosage it could suppress all pituitary hormones (McCann 1982) . Gastrointestinal hormones, gastrin, secretin, cholecystokinin, gastric inhibitory peptide, vasoactive intestinal peptide and motilin are likewise inhibited (Schusdziarra et al. 1978) . Somatostatin can also suppress PRL oversecretion in acromegaly (Yen et al. 1974) .
Due to its very short duration of action and its wide spectrum of effects, somatostatin is not a suitable agent for treating acromegaly. Several analogues are being investigated for a more selective suppression ofGH , Trovati et al. 1980 , Barnes et al. 1981 .
(D-CysI4)-somatostatin has been found to be a more potent inhibitor of GH and glucagon than insulin. Attempts are also being made to prolong its action with preparations such as protarnine-Zn-somatostatin, but not yet with satisfactory results (Tannenbaum & Cole 1980) . Different somatostatin-like polypeptides have been isolated and identified from the hypothalamus of various mammalian sources. The isolation of a 28-aminoacid peptide, somatostatin-28, which has different selective potency on the pancreas and the brain, has been reported (Esch et al. 1980 , Meyers et al. 1980 . Acromegaly could eventually be treated medically if a long-acting, selective somatostatin were obtained.
Dopaminergic drugs: It would appear that dopamine is the specific neurotransmitter for the release of GH-releasing factor from the arcuate nucleus of the hypothalamus (Frohman & Stachura 1975) . In acromegaly an aberrant response to neurotransmitters is observed and paradoxically dopamine will suppress the release of GH (Liuzzi et al. 1972 ). This action is shared by a number of dopaminergic drugs. L-dopa is a precursor of dopamine that passes the blood-brain barrier and in normal subjects stimulates the release of GH (Boyd et al. 1970) . Liuzzi et al. (1972) reported that the acute administration of L-dopa suppressed GH in acromegalic patients. The relative short half-life of L-dopa and its side effects have prevented its wide clinical use. Of the various compounds tested so far, bromocriptine, a long-acting peptide-containing ergot alkaloid, and Iisuride, a simple ergo line, are the most effective (Muller et al. 1981) .
Bromocriptine has been widely tried in Europe (Sachdev et al. 1975 , Summers et al. 1975 , Wass et al. 1977 . About a third of acromegalic patients are 'nonresponders' even to high doses. Apart from lowering plasma GH levels, clinical improvement (on soft tissue swelling, headache, paraesthesiae, sweating, hypertension, libido) and metabolic amelioration (on glucose tolerance, hyperprolinuria) have been reported. Resumption of menses and cessation of galactorrhoea may be due to concomitant reduction of hyperprolactinaemia. Clinical improvement has also been observed among 'non-responders or poor responders'. Lamberts et al. (1982) found that acromegalies showing a rise after administration of TRH are better responders to bromocriptine. Drug withdrawal is quickly followed by a rise in GH levels.
Other effects of bromocriptine have been postulated. It has been found that clinical improvement correlates better with somatomedin-C levels than with GH levels, suggesting that bromocriptine may directly· inhibit GH-stimulated somatomedin production (Clemmons et al. 1979 , Wass et al. 1982 . Lindholm et al. (1981) do not consider the efficacy of bromocriptine in acromegaly to be well documented. In a controlled trial of 19 patients who received bromocriptine up to 20 rug/day during 3 months and then a placebo for a similar period, they did not observe any significant clinical or biochemical difference, except for the reduction in plasma PRL.
Reduction in tumour size has been reported (Wass et al. 1979 , Wollesen et al. 1982 ) but this effect of bromocriptine seems to be variable. Salti & Isthan (1979) have communicated progression of enlargement of sella turcica in spite of normalization of serum GH levels. Two cases of confirmed pituitary apoplexy have occurred in the course of long-term bromocriptine therapy (Yamaji et al. 1981) .
In a review of the literature, Vigneri & Goldfine (1980) found that long-term results in major series indicate a fall in GH levels of 50% or more in 75% of patients, but in only 20% of them are levels reduced to normal. The requirement of bromocriptine is usually 10-20 rug/day, which is higher than for the treatment of PRL-secreting tumours. Side effects are therefore more common, but in general bromocriptine is well tolerated.
At present bromocriptine may be considered a useful adjunct to, but not a replacement for, more radical therapeutic approaches to acromegaly. It is especially directed to patients who have had unsuccessful surgery and/or radiation, or those waiting for surgery or for the effect of radiation; elderly, surgically high-risk patients; and patients who refuse other types of therapy '{Muller et al. 1981) .
The other dopaminergic drug, lisuride, has been tried by Liuzzi et al. (1978) who found that 7 of 12 acromegalic patients responded with a drop in serum GH of more than 50% of the baseline; those who did not respond to lisuride did not respond to bromocriptine either.
Dopamine antagonists: Some studies have been made with antipsychotic agents of the phenothiazine group (chlorpromazine) and substituted benzamides (sulpiride). After. the communication by Kolodny et al. (1971) claiming amelioration of the acromegaly syndrome in one patient treated with chlorpromazine, Dimond et al. (1973) carried out a trial in 8 patients and reported no effect in any of them. Haloperidol and pimozide have been effective in reducing GH levels in 4 of 5 acromegalies after failure of bromocriptine (Carmina et al. 1979) .
The effect of sulpiride on GH secretion in acromegaly remains controversial. Schaison et al. (1974) reported diminution in 5 of 9 acromegalies, and Paracchi et al. (1977) in 5 of 13 patients. Verde et al. (1980) found that in 10 of 21 acromegalies GH levels were reduced below 10 ng/ml with doses of lisuride ranging from 0.4 to 2.4 mg/day, but Liuzzi et al. (1980) obtained no significant change in 30 of 33 patients, and clear elevation of GH levels in 3.
Pituitary irradiation
Conventional supervoltage irradiation has proved to be an effective treatment for acromegaly ), but its effects are shown gradually and slowly over the years. In less than half of patients is serum GH reduced to normal (below 5 ng/ml) at 5 years, but in the majority -around 70%this is so by 10 years after treatment. There is no mortality and morbidity is low, but progressive visual failure has been reported in 4 patients in a series of 23, developing 2 months to 6 years after irradiation. In 2 of them, post-mortem confirmed radiation damage to the optic nerves and hypothalamus (Atkinson et al. 1979) . Complete or partial hypopituitarism also develops gradually, affecting up to 50% of patients at 10 years , Aloia & Archambeau 1978 . Development of hyperprolactinaemia secondary to external pituitary irradiation has been confirmed in some cases, probably induced by radiation damage to the hypothalamus (Shalet et al. 1979 , Clark et al. 1982 .
With alpha particle therapy, Linfoot (1979) has observed that at 2 years levels of GH fall below 5 ng/rnl (10 miu/l) in only 30% of patients, but the proportion increases to 70% by 6 years and reaches 95% by 8 years. The number of patients developing hypopituitarism also increases over the years, affecting around one-third of them by 4 years.
In the experience of Kjellberg & Kliman (1979) with the proton beam technique, GH values were reduced below 10 ng/rnl (20 miu/l) in 60% of patients at 2 years and in 80% at 4 years.
The advantage of radiation therapy is that it has no mortality and very low morbidity. Its greatest disadvantages are the delay in response, and secondary hypopituitarism. Neurological complications with alpha particles tend to be minor when compared to cases of radionecrosis following photon therapy (Linfoot 1980) . Rarely, sarcomas have been found to develop after conventional pituitary irradiation, with an average latency period of approximately 8 years (Goldberg et al. 1963 , Waltz & Brownell 1966 , and also after proton" beam radiotherapy (Coppeto 1979) .
Interstitial irradiation of the tumour with Y-90 (Molinatti et af. 1962), Y-90 and Au-198 (Hartog et al. 1965) , or Y-90 and Ir-l92 pituitary implants (Jadresic & Poblete 1967) has also been reported to be useful in treating some acromegalies, particularly those without large tumours. Patients presenting with large suprasellar extensions or empty sella are excluded. A recent reappraisal of the experience with Y-90 at the Hammersmith Hospital reported by Cassar et al. (1981) has shown reduction of serum GH levels below 11 miu/l in 50% of patients at the end of one year. There was no mortality and complications were minor (2 temporary 6th nerve paresia, 2 wound infections), but 7 of 22 patients treated required replacement therapy. Studies of prolonged follow up after Y-90 implants have not yet been published, but we believe that after satisfactory remission there are no relapses of acromegaly (Jadresic, Jimenez & Joplin, unpublished data) . Quabbe (1982) reported similar results among 30 patients implanted with Y-90, although complications were higher.
Surgical treatment
There has been an enormous improvement in surgical treatment of acromegaly in the last decade with the introduction of the trans-sphenoidal microsurgical approach to the pituitary for the removal of adenomas. This route, initially developed by Cushing (1909) , was soon abandoned due to the high risk of infection. With the use of antibiotics, it was reintroduced by Guiot et al. (1958) and by Hardy & Wigser (1965) . At present, by means of intraoperative fluoroscopic monitoring and the use of the operating microscope, it is possible to recognize adenomatous tissue and to remove it selectively. After the operation, the immediate restoration of GH to normal is followed by a dramatic improvement in the clinical condition of patients, diminution of acromegalic features and amelioration of diabetes mellitus or correction of impaired glucose tolerance (Pearson et al. 1981) . Serum GH levels below 5 ng/ml after trans-sphenoidal operation have been reported in 50-80% of patients (Hardy et al. 1976 , Williams et al. 1975 , Arafah et al. 1980 , Richards & Thomas 1980 , Balagura et al. 1981 . Mortality ranges from nil to less than 2%. In the recent report by the Acromegaly Study Group in Germany (Quabbe 1982) on 152 patients from various university clinics, complications such as rhinorrhoea and meningitis were around 7%. Postoperative deterioration of one or more pituitary functions were found in 17% of patients, and restoration of previously impaired pituitary function in 10%.
Results vary not only in relation to the neurosurgeon's experience but also to the philosophy of the managing team of surgeon and endocrinologist, and to the criteria in assessing results of treatment. Some groups aim at selective removal of adenomas (Quabbe 1982 , Teasdale et al. 1982 , while others are of the view that ablation should be as extensive as necessary to ensure total removal of the adenoma even at the risk of inducing hypopituitarism (Pearson et al. 1981 , Thomas 1983 . Results are better in patients with adenomas confined to the pituitary sella than in those with invasive tumours or with suprasellar extension (Pearson et al. 1981 . Balagura et al. 1981 .
Successful treatment of acromegaly has been reported with cryosurgery (Oi Tullo & Rand 1977 , Levin et al. 1974 or by combining trans-sphenoidal microsurgery with additional cryosurgery (Pelkonen & Grahne 1975) , but cryosurgery does not add any advantage to the treatment. Teasdale et al. (1982) have made a comparison of both procedures in their own neurological unit in two groups of 28 patients each, and found that 68% of acromegalies treated by trans-sphenoidal microsurgery obtained serum GH values below 10 miu/l as compared with only 25% of those treated with cryoablation. None of the 21 patients in whom selective tumour removal was attempted lost pituitary function. Complications such as quadrantopsy, meningitis and extraocular muscle weakness occurred in 6 patients treated by cryosurgery and in none of those treated with microsurgery.
Regarding assessment of results after treatment, some authors will rate as satisfactory a drop in serum GH values to less than 10 ng/ml (20 miu/l) (Levin et al. 1974 , Di Tullo & Rand 1977 , and it has been considered that at that level the metabolic effects of GH excess appear to be negligible (Christy 1982) . Other investigators will evaluate as satisfactory a drop below 5 ng/rnl (10 miu/l) (Quabbe 1982 , Teasdale et al. 1982 . To others it is becoming evident that assessment by dynamic tests is more reliable to define cure or persistence of acromegalic activity (Faglia et al. 1978 , Jaquet et al. 1980 . Schuster et al. (1981) suggest that the present enthusiasm for trans-sphenoidal selective pituitary adenomectomy for acromegaly must be tempered by the realization that a significant number of patients may not obtain long-term remission. Seven of II patients treated showed clinical improvement after trans-sphenoidal surgery and their glucosesuppressed GH levels were below 5 ng/rnl; but after 18 to 57 months' follow up, 4 had clinical evidence of a recurrence of acromegaly and glucose-suppressed GH concentration ranged from 6 to 17 ng/ml. These 4 patients showed a rise in serum GH after TRH, and eventually needed additional therapy for acromegaly. All 20 normal controls had a glucosesuppressed GH value below 2 ng/ml. Schuster et al. (1981) conclude that more rigorous criteria for definition of biochemical cure of acromegaly is needed. TRH does not induce a rise in GH in normal subjects, but often induces increased secretion in acromegalies; presumably this comes from the adenomato us cell. Thus, lack of response in the postoperative period indicates complete removal of the adenoma. Faglia et al. (1978) have found that none of the patients who became unresponsive to TRH after removal of an adenoma relapsed during follow up of 18 to 80 months, whereas one of 3 who remained responsive relapsed after 10 months. Arafah et al. (1980) reported similar findings: 3 of 7 who had normal basal serum GH levels, but an abnormal response to tests, relapsed within a year. Clemmons et al. (1979) have proposed evaluation of acromegalic activity by measurement of somatornedin-C, but probably this will not substitute suppression or provocative tests.
Transfrontal hypophysectomy, which was the most popular route in the past (Ray et al. 1968 ), still has a place in operating on large tumours, particularly those with suprasellar extensions.
Of special interest is the rare association of acromegaly with bronchial carcinoid tumours, some of which seem to secrete GH and other GH-releasing factors (GHRF) (Oabek 1974 , Sonksen el al. 1976 . Several authors have communicated the presence of GHRF-like activity from extracts of carcinoid tumours (Saeed uz Zafar et al. 1979 , Shalet et al. 1979 , Frohman et al. 1980 which may determine secondary diffuse adenomatous hyperplasia of pituitary somatotrophs. Two cases have been reported of acromegaly and Cushing's syndrome occurring simultaneously in a patient with a carcinoid tumour (Gorden et al. 1968 , Leveston et al. 1981 ). Removal of pancreatic islet cell tumour producing GHRF has resulted in successful treatment of acromegaly .
Finally, progress has also been made in the surgical correction of facial deformities in acromegalic patients. This is seldom necessary or requested by patients and, although it has beeri performed in active acromegaly (Meerloo 1981) , it is advisable to consider it only after confirmed cure of the disease (Converse & Baker 1978 , Whelan et al. 1982 .
Conclusion
The intense research carried out on acromegaly over the last few years has not yet clarified its aetiopathogenesis. It has, however, produced very important data about the hypothalamic-pituitary relation in this condition, while the growing clinical experience' with its management is undoubtedly providing better possibilities of cure for such patients.
